|
West Bend, WI, March 9, 2009 - Spaulding Clinical Research, LLC a leading provider of Phase I and Cardiac Core Lab services has announced the award of a 240 subject, Thorough QT (TQT) study by a major European pharmaceutical company.
Spaulding Clinical is providing its full suite of services from protocol design and writing, Phase I
study execution, Cardiac Core Lab Services (ECG over-reading), Data-Management/Statistical analysis and Medical Writing. Within this study, Spaulding Clinical is able to provide state-of-the-art services utilizing the most advanced technologies available to monitor, record, analyze and report cardiac and overall clinical trial data.
Daniel Selness, Spaulding's Vice President of Operations said, "the use of the full service approach for studies such as this results in significant quality, time and cost efficiencies that ultimately benefit the Sponsor."
Spaulding has a very unique specialization in Cardiac Safety Testing for new drugs in development and provides the highest quality clinical trial conduct, using the most efficient processes in the industry.
Randy Spaulding, Spaulding Clinical's President and Chief Executive Officer said: "Spaulding Clinical's goal is to become the industry's premier Phase I study service, as measured by data quality, breadth and depth of analysis, project completion time, and cost efficiency, and this study is a significant step towards us attaining that goal".
About Spaulding Clinical
Based near Milwaukee, WI, Spaulding Clinical Research (www.SpauldingClinical.com) is a
Phase 1 Clinical Research Unit and Cardiac Core Lab, offering a range of services including definitive QTc (TQT) studies, first-in-human studies, multiple rising dose, bioavailability and bioequivalence, drug interaction, food effect, and PK/PD characterization. Spaulding Clinical also offers a full suite of Cardiac Core Lab and over-reading services with state-of-the-art technology and cardiac expertise.
Contact:
Spaulding Clinical
Amanda Baltz
262.306.3324
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
|
News and Events 
